Discovery of new bacteria opens fresh avenues for prostate cancer research - News-Medical

News|Articles|October 20, 2026 In a phase 1 trial, CD19/CD20/CD22 CAR T cells produced complete responses in 83% of patients with relapsed/refractory B-cell non-Hodgkin lymphoma. A trispecific chimeric antigen receptor (CAR) T-cell product targeting CD19, CD20, and CD22 with an OX40 costimulatory domain was safely administered to patients with relapsed/refractory B-cell malignancies, with particularly encouraging activity in B-cell non-Hodgkin lymphoma (B-NHL), according to results from a first-in-human phase 1 trial (NCT05418088) published in Blood Cancer Discovery. Successful manufacturing was achieved in 16 of 17 patients, with 1 failure occurring in a heavily pretreated patient with Richter transformation. The median manufacturing time was 7 days (range, 6-10), the median transduction efficiency was 38.8% (range, 16.9%-57.6%), and the median fold expansion was 5.4 (range, 1.4-12.9). No dose-limiting toxicities (DLTs) were observed across the 3 dose levels tested. Cytokine release syndrome (CRS) occurred in 25% of patients and was limited to grade 1 or 2, with a median onset of 8.5 days after infusion.

News|Articles|October 20, 2026 Key TakeawaysBreast cancer mortality is projected to be about 13% higher in rural than urban populations by 2035, or roughly 38 additional deaths per 1 million women. Mortality fell in both groups from 1999 to 2020, but more slowly in rural areas. The absolute gap is expected to grow from about 2 deaths per 100,000 women in 2020 to about 3.8 per 100,000 by 2035. Rural patients had a 21% higher risk of breast cancer-related death before adjustment, which dropped to 3% after accounting for age, race, ethnicity, tumor stage, molecular subtype, and receipt of chemotherapy and radiotherapy.